| GlaxoSmithKline's Sirtris Acquisition Looks Less Promising Following Trial Suspension The Burrill Report submits: By Michael FitzhughGlaxoSmithKline’s (GSK) $720 million acquisition of Sirtris Pharmaceuticals looks a little less rosy this spring, following the May 4 suspension of a mid-stage trial for SRT501, a reformulated version of the red wine component resveratrol.Complete Story » seekingalpha.com |
Study Shows Hope for Gene Therapy Researchers have launched a new gene-therapy trial for children with a rare disease known as "bubble boy syndrome," reflecting fresh hopes that the strategy of delivering working genes can be used to treat many intractable ailments. online.wsj.com |
AstraZeneca Anticlotting Drug Wins Support An FDA panel backed an anticlotting drug being developed by AstraZeneca despite concerns about its effectiveness. online.wsj.com |
Avanir Pharma's Pending FDA Approval: The Upside Potential Rockford Coscia submits: I've been looking rather deeply into Avanir Pharmaceuticals (AVNR) and I have to say I’m impressed. There doesn’t appear to be any red flags I can find apart from some recent insider sales and a recent shelf registration (I’ll come back to this in the next Avanir post). Avanir received an 'approvable letter', now known as a complete response letter (CRL), in 2006 for AVP-923 (formerly known as Zenvia). As AVP-923 faces a new PDUFA decision date of October 30, I wanted to take a look at Avanir and evaluate the progress it has made in terms of safety and efficacy since receipt of the initial FDA response. Complete Story » seekingalpha.com |
When Anxiety, Insomnia Precede Menopause Hormonal shifts in the years leading up to menopause can trigger hot flashes and bone loss. But this life phase, called perimenopause, can affect memory, moods and sleep as well. online.wsj.com |